Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Cream in Participants With Prurigo Nodularis
NCT05755438Phase 3Completed
- Sponsor
- Incyte
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in prurigo nodularis (PN) comparing Vehicle Cream BID with Ruxolitinib 1.5% Cream (2 arms). Primary endpoint: Worst Itch Numeric Rating Scale 4-Point Response at 12 weeks. Started Mar 2023; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT05755438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05755438.